https://www.selleckchem.com/pr....oducts/bay-2416964.h
G compared to Control patients in both blood (3.98 ± 2.24, 2.10 ± 1.29, P less then 0.05) and HTF cells (37.31 ± 22.0, 8.66 ± 10.40, P less then 0.01). Treatment of PXFG HTFs with in 5-azacytidine increased LOXL1 expression when compared with untreated PXFG HTFs (Fold change 2.26 ± 0.67, P less then 0.05). These data demonstrate that LOXL1 expression is altered in PXFG via DNA methylation and that reversal of these epigenetic changes may represent future potential therapeutic targets in the management of PXFG.Chitin nanofibers (ChNF